Showing results (1-10 of 33) with videos related to
Sort By:
Pageof 4
Histopathology|May 3, 2020
Grading of prostate cancer: the impact of including intraductal carcinoma on the overall Grade Group assigned in diagnostic biopsiesDaphne Chen-Maxwell, Susan PrendevilleJournal of Clinical Pathology|August 25, 2016
Lymph node staging in prostate cancer: perspective for the pathologistSusan Prendeville, Theodorus H van der KwastJournal of Clinical Pathology|June 3, 2019
Optimal sampling of pelvic lymphadenectomy specimens following radical prostatectomy: is complete tissue submission justified?Sarah Ni Mhaolcatha, Elaine Power, Nick Mayer, et al.Histopathology|February 28, 2025
Diagnostic accuracy and clinical outcomes of patients diagnosed with clear cell papillary renal cell tumour at renal mass biopsyAlexander Oberc, Carol C Cheung, Satheesh Krishna, et al.American Journal of Clinical Pathology|December 30, 2015
Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case SelectionSusan Prendeville, Linda Feeley, Michael W Bennett, et al.Journal of Clinical Pathology|July 20, 2024
Frequency and clinicopathologic features of renal low-grade oncocytic tumour and eosinophilic vacuolated tumour: reclassification of 605 eosinophilic tumours including patients managed with active surveillanceRoselyne Choiniere, Shifaa' Al Qa'qa', Carol C Cheung, et al.Histopathology|December 15, 2025
Diagnosing oncocytic renal tumours on renal mass biopsy; pathological concordance and the impact of evolving classificationShifaa' Al Qa'qa', Carol C Cheung, Satheesh Krishna, et al.The Journal of Urology|January 29, 2017
Variant Histology and Clinicopathological Features of Prostate Cancer in Men Younger than 50 Years Treated with Radical ProstatectomySusan Prendeville, Michael E Nesbitt, Andrew J Evans, et al.American Journal of Clinical Pathology|April 29, 2016
Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma: How Many Cells Are Enough?Susan Prendeville, Mark A Corrigan, Vicki Livingstone, et al.Breast (Edinburgh, Scotland)|February 16, 2015
Sentinel lymph node biopsy is not warranted following a core needle biopsy diagnosis of ductal carcinoma in situ (DCIS) of the breastSusan Prendeville, Ciara Ryan, Linda Feeley, et al.Pageof 4